Applying Regional Health Plan Best Practices in the Treatment of Eosinophilic Esophagitis

• Release Date: July 1, 2024
• Expiration Date: December 31, 2025
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with all modern browsers and mobile devices

Expert Faculty California AMCP Affiliate Presenters

Jonathon Toft, PharmD, MBA Principal, Formulary and Rebate Optimization MedImpact Click here for biography Zachary Contreras, PharmD Director, Pharmacy Benefits Sharp Health Plan Click here for biography Anup J. Patel, MD Pediatric Gastroenterologist Children’s Hospital of Orange County Click here for biography Anthony M. Dao, PharmD National Managed Care Director of Pharmacy AIDS Healthcare Foundation Click here for biography Hiva Pourarsalan, PharmD, RPh Director of Pharmacy, Mercy Care Advantage Aetna Click here for biography

Northwest AMCP Affiliate Presenters

Vivien Chan, PharmD GM and Director of Formulary and Contracting Costco Health Solutions Click here for biography Maureen Bauer, MD Associate Professor Pediatric Allergy & Immunology Children’s Hospital Colorado, University of Colorado School of Medicine Click here for biography Carolyn S. Rohrs, Pharm.D. Clinical Pharmacist Consultant, Sr. Regence Pharmacy Services Click here for biography Dan Danielson, BPharm, MS Senior Director, Market Access Solutions Precision for Value Click here for biography

Mid-Atlantic AMCP Affiliate Presenters

Maureen Bauer, MD Associate Professor Pediatric Allergy & Immunology Children’s Hospital Colorado, University of Colorado School of Medicine Click here for biography Gary M. Owens, MD President Gary Owens Associates Click here for biography Drake Reiter, PharmD Director, Clinical and Payer Solutions Strategy RxAnte Click here for biography Erica Shepperd-Debnam, PharmD Ambulatory Clinical Pharmacist Children’s National Hospital Click here for biography Stephanie Spence, PharmD, CSP Director, Specialty Pharmacy CareFirst BCBS Click here for biography

Target Audience
This activity is designed to meet the educational needs of AMCP affiliate members in the roles of pharmacy directors, clinical pharmacists, specialty pharmacists, medical directors, registered nurses, quality directors, and other pharmacists and physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
EoE is difficult to diagnose and treat, and as a result is associated with a high disease burden. Once payer decision makers recognize the disease has consequences and associated costs, they are interested in streamlining and standardizing its management to improve access to appropriate care. Managed care and payer professionals are well positioned to design and implement policies that have a considerable influence on patient access to appropriate care of EoE. Based on findings from previous initiatives, disease state baseline knowledge and awareness still needs to be improved and payers continue to need additional education to apply regional health plan best practices to improve EoE management. Incorporating an understanding of regional variances in EoE into healthcare strategies can ultimately lead to better outcomes for individuals with this condition while optimizing the utilization of healthcare resources and managing costs.

Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss the diagnostic journey of patients with EoE and the importance of early diagnosis
• Assess evidence-based treatment strategies and resources for optimal patient outcomes in EoE
• Employ regional benefit design strategies that facilitate appropriate patient access to evidence-based treatment options for EoE
• Implement collaborative regional payer/provider initiatives to improve the treatment of EoE

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-162-H01-P
Type of Activity: Application

For Pharmacists: Upon successfully completing the activity evaluation form your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.